Vanja Sikirica

Summary

Affiliation: Shire BioChem Inc

Publications

  1. ncbi request reprint Impact of atypical antipsychotic use among adolescents with attention-deficit/hyperactivity disorder
    Vanja Sikirica
    Shire Development LLC, 725 Chesterbrook Blvd, Wayne, PA 19087 e mail
    Am J Manag Care 20:711-21. 2014
  2. pmc Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case
    Hoa H Le
    Pharmacoepidemiology and Pharmacoeconomics, University of Groningen, Antonius Deusinglaan 1, 9713, Groningen, The Netherlands
    Eur Child Adolesc Psychiatry 23:587-98. 2014
  3. pmc Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology
    Vanja Sikirica
    Global Health Economics and Outcomes Research, Shire Development LLC, 725 Chesterbrook Boulevard, Wayne, PA, 19087, USA
    CNS Drugs 27:943-53. 2013
  4. pmc Concomitant pharmacotherapy of psychotropic medications in EU children and adolescents with attention-deficit/hyperactivity disorder
    Vanja Sikirica
    Global Health Economics Outcomes Research and Epidemiology, SHIRE, 725 Chesterbrook Boulevard, Wayne, PA, 19087, USA
    Drugs R D 13:271-80. 2013
  5. ncbi request reprint Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics
    Vanja Sikirica
    Global Health Economics and Outcomes Research, Shire Development LLC, 725 Chesterbrook Blvd, Wayne, PA 19087, USA
    J Manag Care Pharm 18:676-89. 2012
  6. pmc Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents
    Vanja Sikirica
    Global Health Economics and Outcomes Research, Shire Development LLC, 725 Chesterbrook Boulevard, Wayne, PA 19087, USA
    Pharmacoeconomics 30:e1-15. 2012
  7. pmc The inpatient burden of abdominal and gynecological adhesiolysis in the US
    Vanja Sikirica
    Shire Pharmaceuticals, Wayne, PA 19087, USA
    BMC Surg 11:13. 2011
  8. doi request reprint Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison
    M Haim Erder
    Shire Development LLC, Wayne, PA 19087, USA
    Appl Health Econ Health Policy 10:381-95. 2012
  9. doi request reprint Unmet needs associated with attention-deficit/hyperactivity disorder in eight European countries as reported by caregivers and adolescents: results from qualitative research
    Vanja Sikirica
    Global Health Economics, Outcomes Research and Epidemiology, SHIRE, Wayne, PA, USA
    Patient 8:269-81. 2015
  10. doi request reprint Psychometric validation of the Weiss Functional Impairment Rating Scale-Parent Report Form in children and adolescents with attention-deficit/hyperactivity disorder
    Kavita Gajria
    SHIRE, 725 Chesterbrook Boulevard, Wayne, PA, 19087, USA
    Health Qual Life Outcomes 13:184. 2015

Collaborators

Detail Information

Publications11

  1. ncbi request reprint Impact of atypical antipsychotic use among adolescents with attention-deficit/hyperactivity disorder
    Vanja Sikirica
    Shire Development LLC, 725 Chesterbrook Blvd, Wayne, PA 19087 e mail
    Am J Manag Care 20:711-21. 2014
    ....
  2. pmc Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case
    Hoa H Le
    Pharmacoepidemiology and Pharmacoeconomics, University of Groningen, Antonius Deusinglaan 1, 9713, Groningen, The Netherlands
    Eur Child Adolesc Psychiatry 23:587-98. 2014
    ..The limited number of European-based studies examining the economic burden of ADHD highlights the need for more research in this area...
  3. pmc Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology
    Vanja Sikirica
    Global Health Economics and Outcomes Research, Shire Development LLC, 725 Chesterbrook Boulevard, Wayne, PA, 19087, USA
    CNS Drugs 27:943-53. 2013
    ....
  4. pmc Concomitant pharmacotherapy of psychotropic medications in EU children and adolescents with attention-deficit/hyperactivity disorder
    Vanja Sikirica
    Global Health Economics Outcomes Research and Epidemiology, SHIRE, 725 Chesterbrook Boulevard, Wayne, PA, 19087, USA
    Drugs R D 13:271-80. 2013
    ....
  5. ncbi request reprint Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics
    Vanja Sikirica
    Global Health Economics and Outcomes Research, Shire Development LLC, 725 Chesterbrook Blvd, Wayne, PA 19087, USA
    J Manag Care Pharm 18:676-89. 2012
    ..The treatment patterns, resource utilization, and costs associated with AAPs relative to non-antipsychotic medications have not been evaluated for children with ADHD. ..
  6. pmc Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents
    Vanja Sikirica
    Global Health Economics and Outcomes Research, Shire Development LLC, 725 Chesterbrook Boulevard, Wayne, PA 19087, USA
    Pharmacoeconomics 30:e1-15. 2012
    ..However, approximately 30% of children with ADHD do not have an optimal response to a single stimulant and may require adjunctive therapy...
  7. pmc The inpatient burden of abdominal and gynecological adhesiolysis in the US
    Vanja Sikirica
    Shire Pharmaceuticals, Wayne, PA 19087, USA
    BMC Surg 11:13. 2011
    ..This study examines the inpatient burden of adhesiolysis in the United States (i.e., number and rate of events, cost, length of stay [LOS])...
  8. doi request reprint Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison
    M Haim Erder
    Shire Development LLC, Wayne, PA 19087, USA
    Appl Health Econ Health Policy 10:381-95. 2012
    ..ATX has been on the market since 2002 while GXR was recently approved in 2009. To date, there is no comparative effectiveness or cost-effectiveness study comparing the two drugs...
  9. doi request reprint Unmet needs associated with attention-deficit/hyperactivity disorder in eight European countries as reported by caregivers and adolescents: results from qualitative research
    Vanja Sikirica
    Global Health Economics, Outcomes Research and Epidemiology, SHIRE, Wayne, PA, USA
    Patient 8:269-81. 2015
    ..Attention-deficit/hyperactivity disorder (ADHD) is a neurobehavioral disorder characterized by inattention, impulsivity, and hyperactivity, the levels of which are inappropriately high for an individual's developmental age...
  10. doi request reprint Psychometric validation of the Weiss Functional Impairment Rating Scale-Parent Report Form in children and adolescents with attention-deficit/hyperactivity disorder
    Kavita Gajria
    SHIRE, 725 Chesterbrook Boulevard, Wayne, PA, 19087, USA
    Health Qual Life Outcomes 13:184. 2015
    ....